- Home
- Publications
- Publication Search
- Publication Details
Title
Pancreatic Cancer and Immunotherapy: A Clinical Overview
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 16, Pages 4138
Publisher
MDPI AG
Online
2021-08-18
DOI
10.3390/cancers13164138
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
- (2021) Eryn Blass et al. Nature Reviews Clinical Oncology
- Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer
- (2021) Shuxin Sun et al. CANCER LETTERS
- Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol
- (2021) Bart Geboers et al. Cancers
- ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment for metastatic non-small cell lung cancer
- (2020) D. Planchard et al. ANNALS OF ONCOLOGY
- TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial
- (2020) Daniel H. Palmer et al. BRITISH JOURNAL OF CANCER
- Immune checkpoint blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma
- (2020) Changqing Xie et al. CLINICAL CANCER RESEARCH
- Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels
- (2020) Adrian M. Seifert et al. ONCOGENE
- The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
- (2020) Matthew Brown et al. PLoS One
- Immune checkpoint signaling and cancer immunotherapy
- (2020) Xing He et al. CELL RESEARCH
- Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-mesothelin (CRS-207) With or Without Nivolumab in Patients with Pancreatic Cancer
- (2020) Takahiro Tsujikawa et al. CLINICAL CANCER RESEARCH
- Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054
- (2020) Jorge Cebada et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Combination of PD1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer
- (2020) Ying Ma et al. GASTROENTEROLOGY
- Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
- (2020) Keisuke Yamamoto et al. NATURE
- BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
- (2020) Bruno Bockorny et al. NATURE MEDICINE
- High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy
- (2020) Bart Geboers et al. RADIOLOGY
- CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy
- (2020) Hyung-seung Jin et al. Cancer Immunology Research
- Immunotherapy for pancreatic cancer: A 2020 update
- (2020) Dimitrios Schizas et al. CANCER TREATMENT REVIEWS
- A Phase 2 Study of Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer
- (2020) Annie A. Wu et al. CLINICAL CANCER RESEARCH
- Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis
- (2020) Jeffrey H. Lin et al. JOURNAL OF EXPERIMENTAL MEDICINE
- cGAS-STING, an important pathway in cancer immunotherapy
- (2020) Minlin Jiang et al. Journal of Hematology & Oncology
- Oncolytic viruses for cancer immunotherapy
- (2020) Otto Hemminki et al. Journal of Hematology & Oncology
- Tumor microenvironment immune response in pancreatic ductal adenocarcinoma patients treated with neoadjuvant therapy
- (2020) Theodoros Michelakos et al. JNCI-Journal of the National Cancer Institute
- Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire
- (2020) Sebastian P. Haen et al. Nature Reviews Clinical Oncology
- Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
- (2020) Lorenzo Galluzzi et al. Nature Reviews Clinical Oncology
- A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma
- (2020) Conor O’Neill et al. SURGERY
- Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
- (2020) Sai Ping Lau et al. Journal for ImmunoTherapy of Cancer
- Tim-3 finds its place in the cancer immunotherapy landscape
- (2020) Nandini Acharya et al. Journal for ImmunoTherapy of Cancer
- The Age of Cyclic Dinucleotide Vaccine Adjuvants
- (2020) Himanshu Gogoi et al. Vaccines
- New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
- (2020) Iñaki Etxeberria et al. ESMO Open
- Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial
- (2020) KAZUHIRO NAGAI et al. ANTICANCER RESEARCH
- A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
- (2020) Patrick A. Ott et al. CELL
- Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer
- (2020) Tatsuo Kumai et al. CYTOTHERAPY
- The Immune Microenvironment in Pancreatic Cancer
- (2020) Magdalena Huber et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy
- (2020) David M. Francis et al. Science Translational Medicine
- The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data
- (2020) Axel Bengtsson et al. Scientific Reports
- OX40 and OX40L interaction in cancer
- (2020) Xinjie Lu CURRENT MEDICINAL CHEMISTRY
- CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
- (2020) Mark H O'Hara et al. LANCET ONCOLOGY
- Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth
- (2020) Manisit Das et al. Translational Oncology
- CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma
- (2020) Stephen T. Muth et al. CANCER LETTERS
- Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors
- (2020) M.E. Lorkowski et al. JOURNAL OF CONTROLLED RELEASE
- Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma
- (2020) Liming Zhang et al. MOLECULAR THERAPY
- Evaluating the Regulatory Immunomodulation Effect of Irreversible Electroporation (IRE) in Pancreatic Adenocarcinoma
- (2019) Harshul Pandit et al. ANNALS OF SURGICAL ONCOLOGY
- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
- (2019) Arnaud Scherpereel et al. LANCET ONCOLOGY
- Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer
- (2019) Jun Zhao et al. Nature Communications
- Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
- (2019) Kyung Hae Jung et al. CLINICAL CANCER RESEARCH
- Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features
- (2019) Eva Karamitopoulou BRITISH JOURNAL OF CANCER
- A randomized Phase 2b study of GVAX pancreas and CRS-207 compared to chemotherapy in previously-treated metastatic pancreatic adenocarcinoma patients (ECLIPSE Study)
- (2019) Dung T. Le et al. CLINICAL CANCER RESEARCH
- STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models
- (2019) Weiqing Jing et al. Journal for ImmunoTherapy of Cancer
- Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA ‐A24‐positive pancreatic adenocarcinoma
- (2019) Hiroaki Shima et al. CANCER SCIENCE
- Phase I study of lentiviral-transduced chimeric antigen receptor modified T cells recognizing mesothelin in advanced solid cancers
- (2019) Andrew R. Haas et al. MOLECULAR THERAPY
- Toll-like receptor 1 predicts favorable prognosis in pancreatic cancer
- (2019) Mira Lanki et al. PLoS One
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- (2019) Eileen M. O’Reilly et al. JAMA Oncology
- CD40 Agonist Antibodies in Cancer Immunotherapy
- (2019) Robert H. Vonderheide Annual Review of Medicine
- A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors
- (2019) Toshihiko Doi et al. CLINICAL CANCER RESEARCH
- Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model
- (2019) Jayanth S. Shankara Narayanan et al. Cancer Immunology Research
- A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients
- (2019) Michal Bassani-Sternberg et al. Frontiers in Immunology
- Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation
- (2019) Hester J. Scheffer et al. OncoImmunology
- Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma
- (2019) Chi Lin et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study
- (2019) Devalingam Mahalingam et al. CLINICAL CANCER RESEARCH
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
- (2019) Suneel D. Kamath et al. ONCOLOGIST
- The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer
- (2019) Katherine A. Michaelis et al. Nature Communications
- Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment
- (2019) Bradley N. Mills et al. Cell Reports
- WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study
- (2018) ANTICANCER RESEARCH
- A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer
- (2018) Yoshiki Hirooka et al. BMC CANCER
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- (2018) Frederick Arce Vargas et al. CANCER CELL
- Armed oncolytic viruses: A kick-start for anti-tumor immunity
- (2018) J.F. de Graaf et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy
- (2018) Florent Amatore et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
- (2018) Gregory L. Beatty et al. GASTROENTEROLOGY
- The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis
- (2018) He-Li Gao et al. Hepatobiliary & Pancreatic Diseases International
- Immunotherapy for Pancreatic Cancer: More Than Just a Gut Feeling
- (2018) Erick Riquelme et al. Cancer Discovery
- Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study
- (2018) Sumiyuki Nishida et al. Cancer Immunology Research
- Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy
- (2018) Rille Pihlak et al. Cancers
- Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy
- (2018) Neus Martinez-Bosch et al. Cancers
- Chemotherapy Combines Effectively with Anti–PD-L1 Treatment and Can Augment Antitumor Responses
- (2018) Rafael Cubas et al. JOURNAL OF IMMUNOLOGY
- Toll-like receptor 2 and Toll-like receptor 4 predict favorable prognosis in local pancreatic cancer
- (2018) Mira A Lanki et al. TUMOR BIOLOGY
- ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17/Th1 T cell response against unglycosylated MUC1 antigen
- (2018) Rebecca K. Carrell et al. VACCINE
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines
- (2018) Shuichi Hanada et al. Human Vaccines & Immunotherapeutics
- Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer
- (2018) Sayeda Yasmin-Karim et al. Frontiers in Immunology
- Radiotherapy and immune response: the systemic effects of a local treatment
- (2018) HA Carvalho et al. Clinics
- Biomaterials for vaccine-based cancer immunotherapy
- (2018) Rui Zhang et al. JOURNAL OF CONTROLLED RELEASE
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
- (2018) Derin B. Keskin et al. NATURE
- Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
- (2018) Andrew McGuigan et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword
- (2017) Marion Dajon et al. IMMUNOBIOLOGY
- TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
- (2017) Wenwen Du et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
- (2017) Glen J. Weiss et al. INVESTIGATIONAL NEW DRUGS
- Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment
- (2017) Mao Lin et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors
- (2017) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer
- (2017) Yoshitaro Shindo et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer
- (2017) Shikhar Mehrotra et al. Journal of Hematology & Oncology
- Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility complex class I-related chain A/B expression
- (2017) Takashi Murakami et al. JOURNAL OF SURGICAL ONCOLOGY
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
- (2017) Alice O. Kamphorst et al. SCIENCE
- High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients
- (2017) Joni Leppänen et al. VIRCHOWS ARCHIV
- Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy
- (2017) Julie Jacobs et al. Oncotarget
- Use of adjuvants for immunotherapy
- (2017) Luisa Circelli et al. Human Vaccines & Immunotherapeutics
- On the significance of Tim-3 expression in pancreatic cancer
- (2017) Pu-ji Peng et al. SAUDI JOURNAL OF BIOLOGICAL SCIENCES
- A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
- (2017) Jeremy B. Foote et al. Cancer Immunology Research
- Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
- (2017) Jiang Chen et al. Journal of Immunology Research
- Paradoxical Role of HMGB1 in Pancreatic Cancer: Tumor Suppressor or Tumor Promoter?
- (2016) MARÍA JOSÉ GARCÍA CEBRIÁN et al. ANTICANCER RESEARCH
- Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
- (2016) Angus G Dalgleish et al. BRITISH JOURNAL OF CANCER
- Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study
- (2016) Nobuaki Suzuki et al. CANCER SCIENCE
- Toll-like receptor 4 promotes angiogenesis in pancreatic cancer via PI3K/AKT signaling
- (2016) Yunliang Sun et al. EXPERIMENTAL CELL RESEARCH
- Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients
- (2016) Motoki Miyazawa et al. INTERNATIONAL JOURNAL OF CANCER
- Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineage
- (2016) Irina Ushach et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
- (2016) Katsuhiko Uesaka et al. LANCET
- Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma
- (2016) Anne M Noonan et al. MOLECULAR THERAPY
- Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies
- (2016) Mohammad A. Jafri et al. Genome Medicine
- Adjuvants for peptide-based cancer vaccines
- (2016) Hiep Khong et al. Journal for ImmunoTherapy of Cancer
- Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma
- (2015) Laura K. Aguilar et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors
- (2015) J. R. Baird et al. CANCER RESEARCH
- Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study
- (2015) Hiroki Yamaue et al. CANCER SCIENCE
- Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer
- (2015) Shuhei Mayanagi et al. CANCER SCIENCE
- Systemic Immune Activity Predicts Overall Survival in Treatment-Nai ve Patients with Metastatic Pancreatic Cancer
- (2015) M. R. Farren et al. CLINICAL CANCER RESEARCH
- Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer
- (2015) C. J. Whatcott et al. CLINICAL CANCER RESEARCH
- Prospective study of the safety and efficacy of a pancreatic cancer stem cell vaccine
- (2015) Mao Lin et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
- (2015) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- TLR9 ligation in pancreatic stellate cells promotes tumorigenesis
- (2015) Constantinos P. Zambirinis et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Activation of Toll-like receptor 7 inhibits the proliferation and migration, and induces the apoptosis of pancreatic cancer cells
- (2015) BING-BING ZOU et al. Molecular Medicine Reports
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy
- (2015) Shintaro Tsukinaga WORLD JOURNAL OF GASTROENTEROLOGY
- Survivin expression and serum levels in pancreatic cancer
- (2015) He Dong et al. World Journal of Surgical Oncology
- Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors
- (2015) Sebastian Schölch et al. Oncotarget
- Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells
- (2015) Joyce M. van Dodewaard-de Jong et al. OncoImmunology
- A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
- (2014) M. Aglietta et al. ANNALS OF ONCOLOGY
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- TIGIT and CD226: Tipping the Balance between Costimulatory and Coinhibitory Molecules to Augment the Cancer Immunotherapy Toolkit
- (2014) Kristen E. Pauken et al. CANCER CELL
- Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)-Specific MHC Class I/II-Restricted Epitopes for Pancreatic Cancer
- (2014) S. Koido et al. CLINICAL CANCER RESEARCH
- Pancreatic stellate cells and pancreas cancer: Current perspectives and future strategies
- (2014) Jonathan Haqq et al. EUROPEAN JOURNAL OF CANCER
- Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer
- (2014) Sumiyuki Nishida et al. JOURNAL OF IMMUNOTHERAPY
- Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
- (2014) Gary Middleton et al. LANCET ONCOLOGY
- Pancreatic Adenocarcinoma
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Carcinoembryonic Antigen-Related Cell Adhesion Molecules (CEACAM) 1, 5 and 6 as Biomarkers in Pancreatic Cancer
- (2014) Florian Gebauer et al. PLoS One
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
- (2013) B. D. Curti et al. CANCER RESEARCH
- Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies
- (2013) K. Sideras et al. CANCER TREATMENT REVIEWS
- Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects
- (2013) M. F. Fransen et al. CLINICAL CANCER RESEARCH
- A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
- (2013) G. L. Beatty et al. CLINICAL CANCER RESEARCH
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
- (2013) Helmut Oettle et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
- (2013) Dung T. Le et al. JOURNAL OF IMMUNOTHERAPY
- A Phase I Clinical Trial of Vaccination With KIF20A-derived Peptide in Combination With Gemcitabine For Patients With Advanced Pancreatic Cancer
- (2013) Nobuaki Suzuki et al. JOURNAL OF IMMUNOTHERAPY
- Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer
- (2013) Shingo Asahara et al. Journal of Translational Medicine
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients
- (2013) SHIGERU YUTANI et al. ONCOLOGY REPORTS
- Mesothelin Binding to CA125/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP-7 Activation
- (2013) Shih-Hsun Chen et al. Scientific Reports
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
- (2012) Paolo P. Provenzano et al. CANCER CELL
- CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth
- (2012) C. Claus et al. CANCER RESEARCH
- Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients
- (2012) Hidekazu Kameshima et al. CANCER SCIENCE
- Mutated Ras-Transfected, EBV-Transformed Lymphoblastoid Cell Lines as a Model Tumor Vaccine for Boosting T-Cell Responses Against Pancreatic Cancer: A Pilot Trial
- (2012) Boris Kubuschok et al. HUMAN GENE THERAPY
- Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study
- (2012) Ying Qiu et al. International Journal of Clinical Oncology
- A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
- (2012) Andrea Wang-Gillam et al. INVESTIGATIONAL NEW DRUGS
- Tumor Immunotherapy Directed at PD-1
- (2012) Antoni Ribas NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma
- (2011) Lutz Eric et al. ANNALS OF SURGERY
- Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study
- (2011) Christian Bauer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
- (2011) Rachel F. Gabitass et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer
- (2011) Yefei Rong et al. CLINICAL AND EXPERIMENTAL MEDICINE
- A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
- (2011) D. T. Le et al. CLINICAL CANCER RESEARCH
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and Immunologic Evaluation of Dendritic Cell–Based Immunotherapy in Combination With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma
- (2011) Yukino Kimura et al. PANCREAS
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine
- (2010) Ghassan K. Abou-Alfa et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Pancreatic adenocarcinoma exerts systemic effects on the peripheral blood myeloid and plasmacytoid dendritic cells: an indicator of disease severity?
- (2010) Vegard Tjomsland et al. BMC CANCER
- Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer
- (2010) K Imai et al. BRITISH JOURNAL OF CANCER
- Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75
- (2010) M C Ryan et al. BRITISH JOURNAL OF CANCER
- A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer
- (2010) A Nakao et al. CANCER GENE THERAPY
- An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma
- (2010) Collin Jacobs et al. INTERNATIONAL JOURNAL OF CANCER
- Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras
- (2010) Synne Wedén et al. INTERNATIONAL JOURNAL OF CANCER
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
- (2010) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study
- (2010) Jean-Luc Van Laethem et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer
- (2010) Miho Kaida et al. JOURNAL OF IMMUNOTHERAPY
- Circulating Myeloid Dendritic Cells as Prognostic Factors in Patients with Pancreatic Cancer Who Have Undergone Surgical Resection
- (2010) Tomohisa Yamamoto et al. JOURNAL OF SURGICAL RESEARCH
- A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients
- (2010) Noguchi ONCOLOGY REPORTS
- Clinical Significance of B7-H1 and B7-1 Expressions in Pancreatic Carcinoma
- (2010) Liancai Wang et al. WORLD JOURNAL OF SURGERY
- Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer
- (2009) Motoki Miyazawa et al. CANCER SCIENCE
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
- (2009) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- Clinical significance of vascular endothelial growth factor and connexin43 for predicting pancreatic cancer clinicopathologic parameters
- (2009) Qi-Lian Liang et al. MEDICAL ONCOLOGY
- Unleashing the therapeutic potential of NOD-like receptors
- (2009) Kaoru Geddes et al. NATURE REVIEWS DRUG DISCOVERY
- Route of Administration of the TLR9 Agonist CpG Critically Determines the Efficacy of Cancer Immunotherapy in Mice
- (2009) Stefan Nierkens et al. PLoS One
- Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer
- (2008) M. Li et al. MOLECULAR CANCER THERAPEUTICS
- Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
- (2008) A M Krieg ONCOGENE
- The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy
- (2008) E. L. J. M. Smits et al. ONCOLOGIST
- The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
- (2008) D. Y.-w. Lin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now